AAV-mediated REP1 gene replacement for choroideremia

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 2 trial. Mid-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 3 Apr 2015: Trial registered, NCT02407678
  2. 16 Aug 2016: Trial started, NCT02407678

The trials

NCT02407678: REP1 Gene Replacement Therapy for Choroideremia

State
Completed
Phase
Phase 2
People
30 planned
Started
16 Aug 2016
Primary completion
23 Jul 2021
Arms
Treatment
Results
None posted
  1. 3 Apr 2015: Trial registered
  2. 16 Aug 2016: Trial started
  3. 23 Jul 2021: Trial completed

How the status changed

  1. 19 Nov 2026: First set: Phase 2 trial

About the treatment

Kind of treatment: Gene therapy.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.